GLP-1 receptor agonists are transforming obesity and diabetes care, but may reduce skeletal muscle mass, raising concerns ...

In new Phase III trial data released Tuesday, people taking orforglipron lost substantially more weight than people taking a ...

France's medicine safety agency has decided to broaden access to Wegovy and Mounjaro, which are not reimbursed by the French ...

A 6-week randomized trial found that tirzepatide significantly reduced energy intake, appetite, and cravings in adults with overweight or obesity, outperforming liraglutide and placebo. Brain ...

Obesity is a major driver of low testosterone in men, a condition known as metabolic hypogonadism. Excess fat, particularly ...

Serena Williams recently shared that she started taking the GLP-1 drug Zepbound after having her two children. The tennis ...

Millions of Americans who have dropped pounds and boosted their health using popular obesity drugs like Wegovy are facing a ...

A higher proportion of sleep medicine providers vs. patients reported CPAP over tirzepatide as their preferred treatment option for comorbid obesity and obstructive sleep apnea, according to data ...

The anti-obesity medication semaglutide (Wegovy) 'took things up one big notch, and now tirzepatide [which is still awaiting approval for weight loss] is up a little notch above that,' one expert ...

Viking Therapeutics (VKTX 5.71%) fell a whopping 39.2% from their previous close on Tuesday, Aug. 19. Investors were reacting ...

Tirzepatide has been shown to be effective in OSA, but evidence related to comorbid insomnia and sleep apnea (COMISA) is lacking.